Mohamedtaki Tejani

Medical Director - Gastrointestinal (GI) Oncology Program

Clinical Cancer Research

Expertise of Mohamedtaki Tejani

Biography: Mohamedtaki A. Tejani, MD, received his Bachelor of Arts degree, Magna Cum Laude, from Amherst College. He later earned his medical degree from Dartmouth Medical School. Dr. Tejani went on to complete his residency at Yale-New Haven Hospital in New Haven, CT, achieving the rank of Chief Resident. Following this, he completed his fellowship training in hematology/oncology at Fox Chase Cancer Center/Temple University in Philadelphia. An award-winning physician, Dr. Tejani has authored numerous oncology-related publications. His research experience and areas of interest include gastrointestinal cancers, biomarkers and therapeutics, patient-provider communication and the culture of medicine. Dr. Tejani firmly believes that patient care is a privilege. Listening and responding to a patient’s unique story is critical in helping that family on their cancer journey. Originally from Tanzania (East Africa), he is fluent in Swahili, Hindi, Urdu and Gujarati.
Education: University of Rochester School of Medicine, Rochester, NY
Residency: Yale-New Haven Medical Center, New Haven, CT
Fellowship: Fox Chase Cancer Center/Temple University, Philadelphia, PA

Publications

A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer

2024, FUTURE ONCOLOGY
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma

2024, ONCOLOGIST
Zanidatamab (zani) in previously treated HER2+biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study

2024, JOURNAL OF CLINICAL ONCOLOGY

More sources loaded
Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States

2023, WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study

2023, ANNALS OF ONCOLOGY
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

2023, LANCET ONCOLOGY
Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma

2022, ONCOLOGIST
Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma

2022, ANNALS OF ONCOLOGY
A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC)

2022, ANNALS OF ONCOLOGY
Comparing Needles and Methods of Endoscopic Ultrasound-Guided Fine-Needle Biopsy to Optimize Specimen Quality and Diagnostic Accuracy for Patients With Pancreatic Masses in a Randomized Trial

2021, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

Associated Clinical Trials for Mohamedtaki Tejani

NCT06203600

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ? 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

This study is currently enrolling.

Associated Conditions: Esophageal Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

This study is being done to answer the following questions: Can adding a drug to the usual treatment for advanced stomach and esophageal cancers make it less likely that these cancers will grow or...
NCT06006923

Randomized trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer

This study is currently enrolling.

Associated Conditions: Colorectal Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

This is a research study to find out if researchers can lower the chance of your colorectal cancer growing or spreading by using a combination of regorafenib and pembrolizumab compared to...
NCT06346392

D9802C00001 (CLARITY GC01): A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

This study is currently enrolling.

Associated Conditions: Esophageal Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

We are doing this study to learn more about: the effectiveness and safety of the investigational study drug AZD0901 compared to a standard therapy that will be selected by your study doctor per your...

More clinical trials loaded
NCT06356311

MK2870-015: A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)

This study is currently enrolling.

Associated Conditions: Esophageal Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

To compare MK-2870 to TPC
with respect to OS.To compare MK-2870 to TPC with respect to PFS per RECIST 1.1 as assessed by BICR. To compare MK-2870 to TPC with respect to ORR per RECIST 1.1 as assessed...
NCT05865535

AV-380-22-102: A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels

This study is currently enrolling.

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

The study involves research. The purpose of the study is to see if a single dose and multiple doses of the study drug, AV 380, are safe and tolerated in cancer participants. This study will also help...
NCT05610163

THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

This study is currently enrolling.

Associated Conditions: Colorectal Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

To evaluate and compare the cCR rates in patients with locally advanced rectal cancer treated with neoadjuvant LCRT followed by neoadjuvant mFOLFIRINOX versus neoadjuvant LCRT followed by neoadjuvant...
NCT05506943

A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen

This study is currently enrolling.

Associated Conditions: Biliary Tract Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida
NCT05174169

NRG-GI008: COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

This study is currently enrolling.

Associated Conditions: Colorectal Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

ctDNA-ve Cohort (Arms 1 + 2): Phase II: To compare time to ctDNA (+ve) status in ctDNA (-ve) cohort following resection of stage III colon cancer treated with immediate vs delayed (based on serial...
NCT04793958

A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

This study is currently enrolling.

Associated Conditions: Colorectal Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

This is a study involving an investigational (experimental) drug called MRTX849, being developed by Mirati Therapeutics, Inc., which is the company that provides MRTX849 study drug and is funding and...
NCT04935359

A randomized, three-arm, double-blind, placebo-controlled, phase III study, comparing NIS793 with or without spartalizumab in combination with gemcitabine and nab-paclitaxel versus matching placebos combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

This study is not currently enrolling.

Associated Conditions: Pancreatic Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line mPDAC. This study...